Stay updated on Pembrolizumab Combo in Advanced Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Advanced Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Advanced Ovarian Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedRevision tag updated from v3.5.3 to v3.5.4, indicating a new version of the page's content or styling. This change appears to be a maintenance/update rather than an alteration to the study details or content.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check32 days agoChange DetectedUpdated the page’s revision/version indicator from v3.5.2 to v3.5.3, reflecting a minor platform or display update rather than a substantive change to the study record.SummaryDifference0.0%

- Check39 days agoChange DetectedRevision: v3.5.2 updated from v3.5.0.SummaryDifference0.0%

- Check68 days agoChange DetectedSite revision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check75 days agoChange DetectedPage revision updated to v3.4.3; previous revision v3.4.2 was removed.SummaryDifference0.0%

- Check97 days agoChange DetectedFallopian Tube Cancer is now listed among the study's conditions, expanding the scope of eligible diseases. This clarifies the target patient population and improves searchability and eligibility assessment.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo in Advanced Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Advanced Ovarian Cancer Clinical Trial page.